The ADAMs family of proteases: New biomarkers and therapeutic targets for cancer?

被引：164
作者：
Duffy M.J. [1 ,2 ]
Mullooly M. [1 ,2 ]
O'Donovan N. [3 ]
Sukor S. [2 ,4 ]
Crown J. [4 ]
Pierce A. [1 ,2 ]
McGowan P.M. [1 ,2 ]
机构：
[1] Department of Pathology and Laboratory Medicine, St. Vincent's University Hospital
[2] UCD School of Medicine and Medical Science, Conway Institute of Biomolecular and Biomedical Research, University College Dublin
[3] National Institute for Cellular Biotechnology, Dublin City University
[4] Department of Medical Oncology, St Vincent's University Hospital
来源：
Clinical Proteomics | 2011年 / 8卷 / 1期
关键词：
Breast Cancer; Trastuzumab; Lapatinib; GW2974; ADAM Protein;
D O I：
10.1186/1559-0275-8-9
中图分类号：
学科分类号：
摘要：
The ADAMs are transmembrane proteins implicated in proteolysis and cell adhesion. Forty gene members of the family have been identified, of which 21 are believed to be functional in humans. As proteases, their main substrates are the ectodomains of other transmembrane proteins. These substrates include precursor forms of growth factors, cytokines, growth factor receptors, cytokine receptors and several different types of adhesion molecules. Although altered expression of specific ADAMs has been implicated in different diseases, their best-documented role is in cancer formation and progression. ADAMs shown to play a role in cancer include ADAM9, ADAM10, ADAM12, ADAM15 and ADAM17. Two of the ADAMs, i.e., ADAM10 and 17 appear to promote cancer progression by releasing HER/EGFR ligands. The released ligands activate HER/EGFR signalling that culminates in increased cell proliferation, migration and survival. Consistent with a causative role in cancer, several ADAMs are emerging as potential cancer biomarkers for aiding cancer diagnosis and predicting patient outcome. Furthermore, a number of selective ADAM inhibitors, especially against ADAM10 and ADAM17, have been shown to have anti-cancer effects. At least one of these inhibitors is now undergoing clinical trials in patients with breast cancer. © 2011 Duffy et al; licensee BioMed Central Ltd.
引用
收藏
相关论文
共 80 条
[71]  
Infante J., Burris H.A., Lewis N., A multicenter phase Ib study of the safety, pharmacokinetics, biological activity and clinical efficacy of INCB7839, a potent and selective inhibitor of ADAM10 and ADAM17, Breast Cancer Res Treat, 106, SUPPL., (2007)
[72]  
Newton R.C., Bradley E.C., Levy R.S., Clinical benefit of INCB7839, a potential and selective ADAM inhibitor, in combination with trastuzumab in patients with metastatic HER2-positive breast cancer, J Clin Oncol, 28, SUPPL., (2010)
[73]  
Merchant N.B., Voskresensky I., Rogers C.M., LaFleur B., Dempsey P.J., Graves-Deal R., Revetta F., Foutch A.C., Rothenberg M.L., Washington M.K., Coffey Jr. R.J., TACE/ADAM-17: A component of the epidermal growth factor receptor axis and a promising therapeutic target in colorectal cancer, Clinical Cancer Research, 14, 4, pp. 1182-1191, (2008)
[74]  
Hundhausen C., Misztela D., Berkhout T.A., Broadway N., Saftig P., Reiss K., Hartmann D., Fahrenholz F., Postina R., Matthews V., Kallen K.-J., Rose-John S., Ludwig A., The disintegrin-like metalloproteinase ADAM10 is involved in constitutive cleavage of CX3CL1 (fractalkine) and regulates CX3CL1-mediated cell-cell adhesion, Blood, 102, 4, pp. 1186-1195, (2003)
[75]  
Zhang Y., Hegen M., Xu J., Keith Jr. J.C., Jin G., Du X., Cummons T., Sheppard B.J., Sun L., Zhu Y., Rao V.R., Wang Q., Xu W., Cowling R., Nickerson-Nutter C.L., Gibbons J., Skotnicki J., Lin L.-L., Levin J., Characterization of (2R, 3S)-2-({[4-(2-butynyloxy)phenyl]sulfonyl}amino)- N, 3-dihydroxybutanamide, a potent and selective inhibitor of TNF-α converting enzyme, International Immunopharmacology, 4, 14 SPEC.ISS., pp. 1845-1857, (2004)
[76]  
Fingleton B., Matrix metalloproteinases as valid clinical targets, Current Pharmaceutical Design, 13, 3, pp. 333-346, (2007)
[77]  
Zucker S., Cao J., Chen W.-T., Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment, Oncogene, 19, 56, pp. 6642-6650, (2000)
[78]  
Baselga J., Tripathy D., Mendelsohn J., Phase II study of weakly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu overexpressing metastatic breast cancer, J Clin Oncol, 14, pp. 737-744, (1996)
[79]  
Cobleigh M.A., Vogel C.L., Tripathy D., Robert N.J., Scholl S., Fehrenbacher L., Wolter J.M., Paton V., Shak S., Lieberman G., Slamon D.J., Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease, Journal of Clinical Oncology, 17, 9, pp. 2639-2648, (1999)
[80]  
Asakura M., Kitakaze M., Takashima S., Liao Y., Ishikura F., Yoshinaka T., Ohmoto H., Node K., Yoshino K., Ishiguro H., Asanuma H., Sanada S., Matsumura Y., Takeda H., Beppu S., Tada M., Hori H., Higashiyama S., Cardiac hypertrophy is inhibited by antagonism of ADAM12 processing of HB-EGF: Metalloproteinase inhibitors as a new therapy, Nature Medicine, 8, 1, pp. 35-40, (2002)
12345678